XML 26 R11.htm IDEA: XBRL DOCUMENT
v3.25.4

Restructuring, Strategic Transaction and Integration (Notes) | 12 Months Ended
--- | ---
Dec. 31, 2025
Restructuring and Related Activities [Abstract] |
Restructuring and Related Activities Disclosure [Text Block] | RESTRUCTURING, STRATEGIC TRANSACTION AND INTEGRATION Restructuring, strategic transaction and integration expenses were $66.5 million, $59.8 million and $41.3 million in 2025, 2024 and 2023, respectively. Restructuring Restructuring charges net of any reversed accruals were $30.0 million, $19.6 million and $5.7 million in 2025, 2024 and 2023, respectively, which are included in the above restructuring, strategic transaction and integration expenses in our consolidated statement of operations. In 2025, we incurred restructuring charges primarily related to facility closure costs and severance expenses. We adjusted certain severance restructuring accrued balances, shown in the table below under "Other adjustments", to reclass prior year accrued restructuring charges for estimated severance costs to other accounts. In 2024, we incurred restructuring charges primarily related to severance expenses. We adjusted certain severance restructuring accrued balances, shown in the table below under "Other adjustments", as a result of merging Smiths Medical entities during 2024. In 2023, we incurred restructuring charges primarily related to severance expenses. We adjusted certain facility and severance restructuring accrued balances to reverse certain accrued balances that will not be utilized. The following table summarizes the activity in our restructuring-related accrual by major type of cost (in thousands):
|  | Employee & Related Costs |  |  | Facility & Other Closure Costs |  | Total
Accrued balance, January 1, 2024 |  | $ | 2,811 |  |  |  | $ | 757 |  |  | $ | 3,568 |
Charges incurred |  | 18,299 |  |  |  | 1,272 |  |  | 19,571 |
Payments |  | (11,687) |  |  |  | (1,632) |  |  | (13,319) |
Other adjustments(1) |  | 327 |  |  |  | — |  |  | 327 |
Currency translation |  | (212) |  |  |  | 10 |  |  | (202) |
Accrued balance, December 31, 2024 |  | $ | 9,538 |  |  |  | $ | 407 |  |  | $ | 9,945 |
Charges incurred |  | 11,083 |  |  |  | 18,963 |  |  | 30,046 |
Payments |  | (13,805) |  |  |  | (13,734) |  |  | (27,539) |
Other adjustments(2) |  | (900) |  |  |  | — |  |  | (900) |
Currency translation |  | 495 |  |  |  | 101 |  |  | 596 |
Accrued balance, December 31, 2025 |  | $ | 6,411 |  |  |  | $ | 5,737 |  |  | $ | 12,148 |
_______________________________________________ (1) Relates to adjustments to accrued restructuring charges as a result of merging Smiths Medical entities during 2024. (2) Relates to prior year accrued restructuring charges for estimated severances costs that were reclassed to other accounts during the first quarter of 2025. Strategic Transaction and Integration Expenses We incurred $36.5 million, $40.2 million and $35.6 million in strategic transaction and integration expenses in 2025, 2024 and 2023, respectively, which are included in restructuring, strategic transaction and integration expenses in our consolidated statement of operations. The strategic transaction and integration expenses during 2025, 2024 and 2023 were primarily related to consulting expenses and employee costs incurred to integrate our Smiths Medical business acquired in 2022. During 2025, transaction costs also included expenses related to the sale of a 60% ownership in our IV Solutions business.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContent Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration